论文部分内容阅读
目的:观察小细胞肺癌(SCLC)患者病情变化时(肿瘤治疗有效或进展)神经元特异烯醇化酶(NSE)、胃泌素释放肽前体(ProGRP)的变化情况,研究二者的敏感性和与病情变化的一致性。方法:回顾性分析2013年1月~2016年12月在中日友好医院住院治疗的47例SCLC患者病历,记录其临床特征及病情变化前后NSE、ProGRP,进行统计分析。结果 :确诊时不同性别、年龄、吸烟史患者NSE、ProGRP水平无统计学差异(均P>0.05),广泛期患者均高于局限期患者(均P<0.05);当肿瘤治疗有效时,NSE、ProGRP水平均显著下降(均P<0.05);肿瘤进展时,ProGRP显著升高(P<0.05);肿瘤治疗有效时,NSE、ProGRP的变化符合率均为100%,中位下降度分别为70.59%、85.11%;肿瘤进展时,NSE、ProGRP变化符合率均为86%,中位上升率分别为128.57%、86.12%。结论 :NSE、ProGRP可以作为预测SCLC临床分期的辅助标志物;NSE、ProGRP均可反映病情变化,但ProGRP比NSE更灵敏;在SCLC的临床诊治中应加强对NSE、ProGRP的检测。
OBJECTIVE: To observe the changes of neuron specific enolase (NSE) and gastrin-releasing peptide precursor (ProGRP) in patients with small cell lung cancer (SCLC) undergoing disease progression (effective or progression of tumor therapy) and to investigate their sensitivity And consistent with the changes in the condition. Methods: The clinical records of 47 SCLC patients hospitalized in Sino-Japanese Friendship Hospital from January 2013 to December 2016 were retrospectively analyzed. The clinical features and changes of NSE and ProGRP before and after the change were recorded and analyzed statistically. Results: The NSE and ProGRP levels of patients with different gender, age and smoking history at the time of diagnosis were not significantly different (all P> 0.05). Patients in the extensive stage were higher than those in the limited period (all P <0.05). When the tumor was treated effectively, NSE (P <0.05). ProGRP was significantly increased when the tumor progressed (P <0.05). The coincidence rate of NSE and ProGRP was 100% when the tumor was treated effectively, and the median decrease was 70.59% and 85.11% respectively. The coincidence rates of NSE and ProGRP in tumor progression were 86% and the median rising rates were 128.57% and 86.12% respectively. CONCLUSIONS: NSE and ProGRP can be used as auxiliary markers in predicting the clinical staging of SCLC. NSE and ProGRP both reflect the changes of the disease, but ProGRP is more sensitive than NSE. The detection of NSE and ProGRP should be strengthened in the clinical diagnosis and treatment of SCLC.